A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Clinical Trials
Hoffmann-La Roche
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
135 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fundación Cenit Para la Investigación En Neurociencias
Buenos Aires, Argentina
- Inst. Alexander Fleming
Buenos Aires, Argentina
- Hospital Britanico
Ciudad Autonoma Bs As, Argentina
- Centro Medico Austral Omi
Ciudad Autonoma Buenos Aires, Argentina
- Macquarie University Hospital
Macquarie Park, New South Wales, Australia
- Orange Hospital
Orange, New South Wales, Australia
- Icon Cancer Foundation
South Brisbane, Queensland, Australia
- Bendigo Cancer Centre
Bendigo, Victoria, Australia
- St. Joseph'S Healthcare Hamilton
Hamilton, Ontario, Canada
- Princess Margaret Cancer Center
Toronto, Ontario, Canada
- Herlev Hospital
Herlev, Denmark
- Chu Besançon - Hôpital Jean Minjoz
Besançon, France
- Chu de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
Bordeaux, France
- Centre Francois Baclesse
Caen, France
- Centre Jean Perrin
Clermont-Ferrand, France
- Centre Oscar Lambret
Lille, France
- Centre Leon Berard
Lyon, France
- Centre Antoine Lacassagne
Nice, France
- Hopital Europeen Georges Pompidou
Paris, France
- Icans
Strasbourg, France
- Institut Gustave Roussy
Villejuif, France
- Zeisigwaldkliniken Bethanien
Chemnitz, Germany
- Klinikum Der Johann Wolfgang Goethe-Universitaet
Frankfurt, Germany
- Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
- Krankenhaus Martha-Maria Halle-Dölau, Klinik Für Urologie
Halle, Germany
- Uniklinik-Eppendorf
Hamburg, Germany
- Med. Hochschule Hannover, Hämatologie, Hämostaseologie, Onkologie U. Stammzelltransplantation
Hanover, Germany
- Klinikum Rechts Der Isar Der Tu München
München, Germany
- Universitaetsklinikum Muenster
Münster, Germany
- Universitätsklinikum Tübingen
Tübingen, Germany
- Universitätsklinikum Ulm
Ulm, Germany
- Alexandras General Hospital of Athens
Athens, Greece
- Athens Medical Center
Athens, Greece
- Attikon University General Hospital
Athens, Greece
- University Hospital of Larissa
Larissa, Greece
- Diavalkaniko Hospital
Thessaloniki, Greece
- A.O. Universitaria Ospedale Consorziale Policlinico Di Bari
Bari, Apulia, Italy
- Istituto Tumori Napoli
Naples, Campania, Italy
- Azienda Ospedaliero-Universitaria S.Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
- Irst Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, Italy
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Jul 2020
- Primary completion
- 3 Jan 2023
- Completion
- 24 Mar 2025
- Last update posted
- 19 Mar 2026
- Registered enrollment
- 522
- Registry id
- NCT04338269
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.